Latest Nootropics News

Hydralyte USA reported a 6% year-on-year sales increase in Q3 FY25 alongside a significant 42% reduction in operating cash burn, driven by a streamlined US-focused model and new product launches in brain and gut health.

Hydralyte USA reports an 11% sales increase in Q3 2025, driven by strong summer demand and the launch of its innovative Hydralyte Plus Brain Support product featuring nootropics.

Bioxyne Limited reports a remarkable 77% revenue increase in Q2 FY2025 alongside positive operating cash flow, setting the stage for international growth with imminent UK export approvals and planned European manufacturing.

Bioxyne Limited has raised its FY2025 revenue forecast to $25 million, driven by a remarkable 267% increase in first-half revenue and strong momentum from its subsidiary Breathe Life Sciences.